Sign Up Today and Learn More About Benchling Stock

Invest in or calculate the value of your shares in Benchling or other pre-IPO companies through EquityZen's platform.

Get Started

Benchling Stock

Benchling aims to accelerate life science R&D. According to Benchling, their cloud platform empowers researchers with a centralized suite for experiment design, collaboration, and data management. Benchling believes this fosters innovation in biotherapeutics, biofuels, and biomaterials by streamlining workflows and facilitating critical R&D decisions.

Benchling is a cloud-based research platform for life sciences.

About Benchling Stock

Founded

2012

Headquarters

San Francisco, CA, US

Notable Investor

Andreessen Horowitz

Total Funding

425M

Benchling is a modern software platform purpose-built for life science R&D. Benchling claims its platform can help manage techniques like CRISPR, CAR-T immunotherapy, and genetic engineering with a suite of cloud applications to design DNA and collaborate on experiments, manage research workflows, and make critical R&D decisions. Benchling is used for research on biotherapeutics, biofuels, and biomaterials at life science companies and academic labs. 

Benchling was founded in 2012 and is headquartered in San Francisco, California, United States. Notable investors include Thrive Capital, Y Combinator, and SV Angel.

Benchling Press Mentions

Stay in the know about the latest news on Benchling

Investors in Benchling

Discover investors in Benchling stock and explore their portfolio companies

Benchling Management

Leadership team at Benchling

Chief Executive Officer

Sajith Wickramasekara

Chief Financial Officer

Richard Wong

Locked Features

Join now and verify your accreditation status to gain access to:

  • Benchling current valuation
  • Benchling stock price
  • Available deals in Benchling and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Benchling stock?

Accredited investors can buy pre-IPO stock in companies like Benchling through EquityZen funds. These investments are made available by existing Benchling shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Benchling stock?

Shareholders can sell their Benchling stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."